FMR LLC increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 5.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 49,145,056 shares of the company's stock after buying an additional 2,593,910 shares during the period. FMR LLC owned 6.65% of Roivant Sciences worth $567,134,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. The Manufacturers Life Insurance Company increased its position in shares of Roivant Sciences by 10.8% during the third quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company's stock valued at $4,115,000 after buying an additional 34,641 shares during the period. Loomis Sayles & Co. L P grew its stake in Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after acquiring an additional 458,601 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Roivant Sciences by 30.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company's stock worth $31,936,000 after acquiring an additional 646,627 shares during the period. Thompson Siegel & Walmsley LLC purchased a new position in shares of Roivant Sciences during the 3rd quarter valued at $5,927,000. Finally, Whalen Wealth Management Inc. bought a new position in shares of Roivant Sciences in the third quarter worth $224,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
ROIV has been the subject of several research analyst reports. Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $17.93.
Read Our Latest Stock Analysis on Roivant Sciences
Insider Transactions at Roivant Sciences
In related news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares in the company, valued at $7,193,525.50. This trade represents a 13.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of the business's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares of the company's stock, valued at $210,693,701.97. The trade was a 9.99 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,677,309 shares of company stock worth $43,283,184. 7.90% of the stock is currently owned by insiders.
Roivant Sciences Stock Performance
NASDAQ:ROIV traded up $0.02 during mid-day trading on Friday, reaching $12.71. The stock had a trading volume of 2,439,939 shares, compared to its average volume of 5,835,690. The stock has a market capitalization of $9.25 billion, a P/E ratio of 2.25 and a beta of 1.24. The firm has a 50 day moving average price of $11.75 and a two-hundred day moving average price of $11.37. Roivant Sciences Ltd. has a one year low of $9.34 and a one year high of $13.06.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
